Author

Sasikiran Goteti

Observed names: S Goteti, S. Goteti, S.C. Goteti

Institution: Alnylam Pharmaceuticals (United States)

Observed institutions: Indraprastha Apollo Hospitals, Alnylam Pharmaceuticals (United States), Vanderbilt University, AbbVie (United States), Christian-Albrechts-Universität zu Kiel, Massachusetts General Hospital, Aichi Cancer Center, Vall d'Hebron Institute of Oncology, Vanderbilt-Ingram Cancer Center, University of Naples Federico II

OpenAlex ID: A5045407496

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

2016 · M. Martín, A. Chan, et al. · Annals of Oncology · 180

P273 Efficacy and safety of upadacitinib maintenance treatment for moderate to severe Crohn’s disease: Results from the CELEST study

2018 · J Panes, W J Sandborn, et al. · Journal of Crohn s and Colitis · 20

Interim phase 1 part A results for ALN‐APP, the first investigational RNAi therapeutic in development for Alzheimer’s disease

2023 · Sharon Cohen, Simon Ducharme, et al. · Alzheimer s & Dementia · 15

OP022 Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: data from the CELEST study

2018 · S Schreiber, L Peyrin-Biroulet, et al. · Journal of Crohn s and Colitis · 14

Single ascending dose results from an ongoing Phase 1 study of mivelsiran (ALN‐APP), the first investigational RNA interference therapeutic targeting amyloid precursor protein for Alzheimer’s disease

2024 · Sharon Cohen, Simon Ducharme, et al. · Alzheimer s & Dementia · 12

BELLE-3: A Phase III study of the pan-phosphatidylinositol 3-kinase (PI3K) inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced/metastatic breast cancer (BC) pretreated with aromatase inhibitors (AIs) and refractory to mTOR inhibitor (mTORi)-based treatment.

2015 · Angelo Di Leo, Eva Ciruelos, et al. · Journal of Clinical Oncology · 7

Some Practical Considerations for Phase III Studies With Biomarker Evaluations

2014 · Sasikiran Goteti, Samit Hirawat, et al. · Journal of Clinical Oncology · 6

Abstract OT2-3-09: Phase III randomized study of the oral pan-PI3K inhibitor BKM120 with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer resistant to aromatase inhibitor – BELLE-2

2012 · J Baselga, M Campone, et al. · Cancer Research · 5

P533 Correlation of endoscopic and clinical endpoints during induction therapy in patients with moderate-to-severe Crohn’s disease: Analysis from CELEST study

2018 · W J Sandborn, B Feagan, et al. · Journal of Crohn s and Colitis · 3

Identifying and Characterizing Comorbid Cerebral Amyloid Angiopathy in ADNI Participants using Boston Criteria Version 2.0

2025 · Robert W Deering, Neal S Parikh, et al. · Alzheimer s & Dementia

67P Challenges to molecular testing for selecting targeted therapies for oncology patients in India

2021 · V.P.B. Koyyala, P.S. Kulkarni, et al. · Annals of Oncology

P313 Impact of upadacitinib on the general clinical condition of patients with Crohn’s disease (CD): data from the randomised CELEST study

2019 · E V Loftus Jr, D T Rubin, et al. · Journal of Crohn s and Colitis

Works count: 12

Citation count: 262

H-index: 6

I10-index: 5